Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05198752 | A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Stemirna TherapeuticsINDUSTRY | 2 | Oct 17, 2022 | clinicaltrials |
| NCT05095441 |
| A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma |
| unknown |
| Phase 1 |
| 51 |
| ImmVira Pharma Co. LtdINDUSTRY |
| 1 |
| Oct 12, 2022 |
| clinicaltrials |
| NCT05569057 | A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma | unknown | Phase 1 | 100 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 7, 2022 | clinicaltrials |
| NCT04765462 | Allogeneic γδ T Cell Therapy for the Treatment of Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | Chinese PLA General HospitalOTHER | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05522309 | FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid Tumors(FLIGHT) | unknown | Phase 1 | 37 | Etern BioPharma (Shanghai) Co., LtdINDUSTRY | 1 | Oct 4, 2022 | clinicaltrials |
| NCT05150457 | Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 48 | Binacea Pharma, Inc.INDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05457517 | A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 49 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04801095 | A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 100 | Wellmarker BioINDUSTRY | 2 | Sep 16, 2022 | clinicaltrials |
| NCT03634982 | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors | unknown | Phase 1 | 133 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05524194 | 6MW3511 in Patients With Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 272 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Sep 1, 2022 | clinicaltrials |
| NCT05525559 | SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors(FIRST) | unknown | Phase 1 | 34 | Etern BioPharma (Shanghai) Co., LtdINDUSTRY | 1 | Sep 1, 2022 | clinicaltrials |
| NCT05508620 | A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 270 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 23, 2022 | clinicaltrials |
| NCT05508373 | A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 72 | Suzhou Kebo Ruijun Biotechnology Co., LtdINDUSTRY | 1 | Aug 19, 2022 | clinicaltrials |
| NCT05508659 | A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 128 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Aug 19, 2022 | clinicaltrials |
| NCT05505877 | Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 160 | Shanghai Gopherwood Biotech Co., Ltd.INDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT05205421 | A Study of Oncolytic Virus Injection (RT-01) in Patients With Extensive-Stage Small Cell Lung Cancer | unknown | Phase 1 | 20 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05478785 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05378178 | A PhaseⅠStudy of HS-10381 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 51 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 7, 2022 | clinicaltrials |
| NCT03758664 | Clinical Study of ICP-192 in Solid Tumors Patients | unknown | Phase 1 / Phase 2 | 56 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05441046 | Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors | unknown | Phase 1 | 120 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 6, 2022 | clinicaltrials |
| NCT05442996 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 30 | Shanghai Henlius BiotechINDUSTRY | 0 | Jul 5, 2022 | clinicaltrials |
| NCT05429398 | A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor | unknown | Phase 1 | 118 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jun 23, 2022 | clinicaltrials |
| NCT05369312 | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients | unknown | Phase 1 | 230 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT05216965 | A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors | unknown | Phase 1 / Phase 2 | 208 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jun 15, 2022 | clinicaltrials |
| NCT04058587 | A Phase I Trial of Simmitinib in Advanced Solid Tumors | unknown | Phase 1 | 50 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jun 6, 2022 | clinicaltrials |
| NCT05393063 | A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 36 | AkesoINDUSTRY | 0 | May 26, 2022 | clinicaltrials |
| NCT05228600 | YL-13027 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 54 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | May 20, 2022 | clinicaltrials |
| NCT05369286 | A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors | unknown | Phase 1 | 28 | Maxinovel Pty., Ltd.INDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT05370755 | A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors | unknown | Phase 1 | 22 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT05228119 | A Study of Oncolytic Virus Injection (RT-01) in Combination With PD-1 Inhibitor in Patients With Advanced Solid Tumors | unknown | Phase 1 | 50 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05360368 | HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 24 | Shanghai Henlius BiotechINDUSTRY | 1 | May 5, 2022 | clinicaltrials |
| NCT05354843 | SHP2 Inhibitor ET0038 Monotherapy in Patients With Advanced Solid Tumors | unknown | Phase 1 | 37 | Etern BioPharma (Shanghai) Co., LtdINDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT05344742 | A Study of Mitoxantrone Hydrochloride Liposome Injection Combination Therapy in Chinese Patients With Advanced Solid Tumors | unknown | Phase 1 | 116 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Apr 25, 2022 | clinicaltrials |
| NCT05341570 | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 | unknown | Phase 1 | 60 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 22, 2022 | clinicaltrials |
| NCT03646071 | A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 80 | NeuPharma, Inc.INDUSTRY | 1 | Apr 13, 2022 | clinicaltrials |
| NCT04082910 | Metoprolol Treatment for Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05320640 | Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT02637531 | A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 | unknown | Phase 1 | 219 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03835949 | Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer | unknown | Phase 1 | 36 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Apr 1, 2022 | clinicaltrials |
| NCT05202561 | A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors | unknown | Phase 1 | 10 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT05258266 | A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 76 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT05277454 | Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT | unknown | Phase 1 | 113 | Hutchison Medipharma LimitedINDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT05278832 | A Study of QLS31905 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 104 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 14, 2022 | clinicaltrials |
| NCT05246995 | A Phase I Study of IBI325 in Patients With Advanced Solid Tumor | unknown | Phase 1 | 60 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 18, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT03994484 | Study of Dosage Exploration and Pharmacokinetics for HA121-28 Tablets | unknown | Phase 1 | 44 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 10, 2022 | clinicaltrials |
| NCT02630368 | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)(METROmaJX) | unknown | Phase 1 / Phase 2 | 197 | Institut BergoniéOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT04640246 | Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies | unknown | Phase 1 / Phase 2 | 60 | Taiga Biotechnologies, Inc.INDUSTRY | 2 | Feb 2, 2022 | clinicaltrials |
| NCT05118841 | Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Feb 2, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Oct 28, 2022source: clinicaltrials